Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03303950 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03303950 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 6 participants.
The verdict
NCT03303950, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Hematopoietic Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03303950
The ClinicalTrials.gov registry entry for NCT03303950 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03303950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03303950 about?
NCT03303950 is a clinical study titled "Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis". This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of ...
What is the current status of trial NCT03303950?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-03-30. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03303950?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Laboratory Biomarker Analysis (OTHER), Hematopoietic Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03303950?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.